Conference for Early Stage HIV/AIDS Researchers Using Nonhuman Primate Models (R13 Clinical Trial Not Allowed)

The objectives of the meeting(s) supported by this FOA are to provide these early stage HIV/AIDS researchers with guidance on conducting preclinical research to inform clinical trials on reducing the incidence of HIV/AIDS infection, including vaccine development and testing; developing next-generation HIV therapies, including potential cure therapies; treatment of HIV-associated coinfections, comorbidities and complications; and infection prevention strategies. In addition to guidance on translating results to clinical trials, the conference should target developing skills related to networking, grantsmanship, and goal/milestone-driven projects. Conference topics should also include other considerations such as statistical and host genetics considerations; methods to translate the results of NHP studies to clinical trials in humans; and how to develop new NHP research programs to better reflect clinical observations and findings in human HIV/AIDS patients.
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding

Related Links:

This report summarizes a consultation meeting convened by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), on 12 September 2017 to discuss the scientific rationale for selectively testing relevant HIV vaccine candidates in early life that are designed to initiate immune responses for lifelong protective immunity. The urgent need to develop interventions providing durable protective immunity to HIV before sexual debut coupled with the practicality of infant vaccine schedules supports optimizing infant HIV vaccines as a high priority. The panelists discussed the unique o...
Source: Topics in HIV Medicine - Category: Infectious Diseases Authors: Tags: mSphere Source Type: research
Previous studies have established that strain 68-1–derived rhesus cytomegalovirus (RhCMV) vectors expressing simian immunodeficiency virus (SIV) proteins (RhCMV/SIV) are able to elicit and maintain cellular immune responses that provide protection against mucosal challenge of highly pathogenic SIV in rhesus monkeys (RMs). However, these efficacious RhCMV/SIV vectors were replication and spread competent and therefore have the potential to cause disease in immunocompromised subjects. To develop a safer CMV-based vaccine for clinical use, we attenuated 68-1 RhCMV/SIV vectors by deletion of the Rh110 gene encoding the p...
Source: Science Translational Medicine - Category: Biomedical Science Authors: Tags: Research Articles Source Type: research
No abstract available
Source: AIDS - Category: Infectious Diseases Tags: Correspondence Source Type: research
No abstract available
Source: AIDS - Category: Infectious Diseases Tags: Correspondence Source Type: research
Thanks to a $129 million federal grant, the Duke Human Vaccine Institute (DHVI) will continue its now 14-year long effort to develop a vaccine for HIV. The National Institute of Allergy and Infectious Disease has announced a seven-year grant totaling at least $129 million to the DHVI. Under the terms of the grant, the institute could also award an additional $18 million – potentially bringing funding to $147 million.  The grants fund the Duke Consortia for HIV/AIDS Vaccine Development (CHAVD)…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
(Scripps Research Institute) The Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), an international collaboration led by Scripps Research, has received a $129 million grant from the National Institutes of Health to advance next-generation vaccines designed to coax the immune system into producing antibodies capable of disarming numerous strains of HIV.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news
.
Source: AIDS Care - Category: Infectious Diseases Authors: Source Type: research
Abstract The rising prevalence of HIV drug resistance (HIVDR) could threaten gains made in combating the HIV epidemic and compromise the 90-90-90 target proposed by United Nations Programme on HIV/AIDS (UNAIDS) to have achieved virological suppression in 90% of all persons receiving antiretroviral therapy (ART) by the year 2020. HIVDR has implications for the persistence of HIV, the selection of current and future ART drug regimens, and strategies of vaccine and cure development. Focusing on drug classes that are in clinical use, this Review critically summarizes what is known about the mechanisms the virus utiliz...
Source: Cell Host and Microbe - Category: Microbiology Authors: Tags: Cell Host Microbe Source Type: research
[The Herald] Zimbabwe has become the first country in the Sub-Saharan Africa region to complete the successful enrolment of participants who are taking part in the ongoing large-scale HIV vaccine efficacy trials which are currently underway on four continents, covering 12 countries with about 12 669 study participants on board.
Source: AllAfrica News: HIV-Aids and STDs - Category: Infectious Diseases Source Type: news
[Daily News] THE Muhimbili University of Health and Allied Sciences (MUHAS), has embarked on the third stage of HIV vaccine trials involving participants who are at high risk of contracting the disease.
Source: AllAfrica News: HIV-Aids and STDs - Category: Infectious Diseases Source Type: news
More News: AIDS Vaccine | Clinical Trials | Conferences | Contracts | Funding | Genetics | Grants | HIV AIDS | Research | Statistics | Study | Vaccines | Workshops